Gritstone bio And The National Cancer Institute Establish Clinical Trial Agreement To Evaluate A Neoantigen Cell Therapy-Vaccine Combination
Under the terms of the agreement, NCI will identify patients with metastatic cancer that are eligible for adoptive cell transfer based on the presence of a G12V or G12D KRAS mutation (KRASmut). Gritstone will provide the